POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-134804 | Pharmaceuticals and Medical
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Point-of-Care Infectious Disease Diagnostics or Testing Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET
7.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA POINT-OF-CARE INFECTIOUS DISEASE DIAGNOSTICS OR TESTING MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Abbott
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Thermo Fisher Scientific Inc
16.3 Sight Diagnostics Ltd
16.4 Trivitron Healthcare
16.5 bioMérieux SA
16.6 Chembio Diagnostics Inc
16.7 Gene POC
16.8 Siemens Healthineers
16.9 Trinity Biotech
16.10 OJ-Bio Ltd
16.11 F Hoffmann-La Roche Ltd
16.12 BD & Company
16.13 Quest Diagnostics Inc
16.14 Bio-Rad Labs Inc
16.15 Cardinal Health
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types CoveredHBV POC
HIV POC
Clostridium difficile POC
HPV POC
Respiratory syncytial virus (RSV) POC
Other Infectious Disease POC
Influenza/Flu POC
Pneumonia or Streptococcus associated infections
Major Downstream Industry Covered
Clinics
Assisted Living Healthcare Facilities
Home
Laboratories
Hospitals
Others
Companies
Abbott
Thermo Fisher Scientific Inc
Sight Diagnostics Ltd
Trivitron Healthcare
bioMérieux SA
Chembio Diagnostics Inc
Gene POC
Siemens Healthineers
Trinity Biotech
OJ-Bio Ltd
F Hoffmann-La Roche Ltd
BD & Company
Quest Diagnostics Inc
Bio-Rad Labs Inc
Cardinal Health
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.